Corvus Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Corvus Pharmaceuticals, Inc. (CRVS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $57.46 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-03
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $57.46M, a 956.81% increase year-over-year.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $1.00M.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $10.01M, a 711.76% increase year-over-year.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $23.61M, a 8392.09% increase year-over-year.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $40.06M, a 4138.73% increase from fiscal 2016.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $945.00K.
- Corvus Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$8.41M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 11 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $57.46M 10-Q · filed 2018-05-03 | $58.46M derived: sum of 2 quarters · filed 2018-05-03 | $68.47M derived: sum of 3 quarters · filed 2018-05-03 | $92.08M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $11.01M derived: sum of 2 quarters · filed 2018-03-01 | $34.62M derived: sum of 3 quarters · filed 2018-03-01 | $40.06M 10-K · filed 2018-03-01 | |
| 2017-09-30 | $10.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $33.62M derived: sum of 2 quarters · filed 2017-11-02 | $39.05M 10-Q · filed 2017-11-02 | $38.53M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-06-30 | $23.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $29.05M 10-Q · filed 2017-08-03 | $28.52M derived: sum of 3 quarters · filed 2018-05-03 | $29.75M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-03-31 | $5.44M 10-Q · filed 2018-05-03 | $4.91M derived: sum of 2 quarters · filed 2018-05-03 | $6.14M derived: sum of 3 quarters · filed 2018-05-03 | $6.42M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | -$526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $707.00K derived: sum of 2 quarters · filed 2018-03-01 | $985.00K derived: sum of 3 quarters · filed 2018-03-01 | $945.00K 10-K · filed 2018-03-01 | |
| 2016-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.51M derived: sum of 2 quarters · filed 2017-11-02 | $1.47M 10-Q · filed 2017-11-02 | -$74.02M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $238.00K 10-Q · filed 2017-08-03 | -$75.26M derived: sum of 3 quarters · filed 2018-03-01 | $1.69M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | -$40.00K 10-Q · filed 2017-05-04 | -$75.53M derived: sum of 2 quarters · filed 2018-03-01 | $1.41M derived: sum of 3 quarters · filed 2018-03-01 | -$9.84M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$75.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $1.45M derived: sum of 2 quarters · filed 2018-03-01 | -$9.80M derived: sum of 3 quarters · filed 2018-03-01 | -$8.41M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $76.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $65.69M derived: sum of 2 quarters · filed 2016-11-03 | $67.08M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | -$11.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$9.87M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $1.39M 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | $12.52M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |